Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Populationbased survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-14; discussion 1314-5.
Okamura K, Usami T, Nagahama K, Maruyama S, Mizuta E. “Quality of life” assessment of urination in elderly Japanese men and women with some medical problems using International Prostate Symptom Score and King’s Health Questionnaire. Eur Urol 2002; 41: 411-9.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78.
Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006; 49: 1079-86.
Homma Y, Gotoh M. Symptom severity and patient perceptions in overactive bladder: how are they related? BJU Int 2009; 104: 968-72.
Homma Y, Yoshida M, Seki N, Yokoyama O, Kakizaki H, Gotoh M, et al. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score. Urology 2006; 68: 318-23.
Gotoh M, Homma Y, Yokoyama O, Nishizawa O. Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology 2011; 78: 768-73.
Homma Y, Kakizaki H, Yamaguchi O, Yamanishi T, Nishizawa O, Yokoyama O, et al. Assessment of overactive bladder symptoms: comparison of 3-day bladder diary and the overactive bladder symptoms score. Urology 2011;77: 60-4.
Jeong SJ, Homma Y, Oh SJ. Korean version of the overactive bladder symptom score questionnaire: translation and linguistic validation. Int Neurourol J 2011; 15: 135-42.
Kubota Y, Kojima Y, Shibata Y, Imura M, Kohri K, Sasaki S. Correlation between improvements in overactive bladder symptom score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug. Neurourol Urodyn 2011; 30: 1309-14.
Tanaka Y, Masumori N, Tsukamoto T. Urodynamic effects of solifenacin in untreated female patients with symptomatic overactive bladder. Int J Urol 2010; 17: 796-800.
Tsujimura A, Takao T, Miyagawa Y, Yamamoto K, Fukuhara S, Nakayama J, et al. Urgency is an independent factor for sleep disturbance in men with obstructive sleep apnea. Urology 2010; 76: 967-70.
Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD. Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder. Urology 2010; 76: 835-40.
Emberton M, Cornel EB, Bassi PF, Fourcade RO, Gómez JM, Castro R. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract 2008; 62: 1076-86.
Sagnier PP, MacFarlane G, Richard F, Botto H, Teillac P, Boyle P. Results of an epidemiological survey using a modified American Urological Association symptom index for benign prostatic hyperplasia in France. J Urol 1994; 151:1266-70.
Tsukamoto T, Kumamoto Y, Masumori N, Miyake H, Rhodes T, Girman CJ, et al. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J Urol 1995; 154: 391-5.
Choi HR, Chung WS, Shim BS, Kwon SW, Hong SJ, Chung BH, et al. Translation validity and reliability of I-PSS Korean version. Korean J Urol 1996;37: 659-65.
Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-57; discussion 64.
Yamaguchi O, Nishizawa O, Takeda M, Yokoyama O, Homma Y, Kakizaki H, et al. Clinical guidelines for overactive bladder. Int J Urol 2009; 16: 126-42.
Jeong SJ, Homma Y, Oh SJ. Reproducibility study of overactive bladder symptom score questionnaire and its response to treatment (RESORT) in Korean population with overactive bladder symptoms. Qual Life Res 2014;23: 285-92.
Weinberg AC, Brandeis GH, Bruyere J, Tsui JF, Weiss JP, Rutman MP, et al. Reliability and validity of the overactive bladder symptom score in Spanish (OABSS-S). Neurourol Urodyn 2012; 31: 664-8.
Hung MJ, Chou CL, Yen TW, Chuang YC, Meng E, Huang ST, et al. Development and validation of the Chinese overactive bladder symptom score for assessing overactive bladder syndrome in a RESORT study. J Formos Med Assoc 2013; 112: 276-82.